NVGN Share Price

Open 1.55 Change Price %
High 1.80 1 Day 0.00 0.00
Low 1.55 1 Week 0.06 3.68
Close 1.69 1 Month 0.08 4.97
Volume 94327 1 Year -0.20 -10.58
52 Week High 2.85
52 Week Low 0.00
NVGN Important Levels
Resistance 2 1.92
Resistance 1 1.83
Pivot 1.68
Support 1 1.55
Support 2 1.46
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.87 0.00%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LINE 0.18 12.50%
ATEA 1.90 11.76%
ATEA 1.90 11.76%
KITD 0.30 11.11%
SGYPU 10.75 10.26%
LPHI 0.24 9.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Novogen Limited (NASDAQ: NVGN)

NVGN Technical Analysis 2
As on 13th Jan 2017 NVGN Share Price closed @ 1.69 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.94 & Buy for SHORT-TERM with Stoploss of 1.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVGN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NVGN Other Details
Segment EQ
Market Capital 82721968.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.novogen.com
NVGN Address
NVGN
16 - 20 Edgeworth David Avenue
Level 1
Hornsby, NSW 2077
Australia
Phone: 61 2 9476 0344
Fax: 61 2 9476 0388
NVGN Latest News
Interactive Technical Analysis Chart Novogen Limited ( NVGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novogen Limited
NVGN Business Profile
Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. Drug Development includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. Oncology Drug Program involves the development of selected oncology drug candidates, which have indicated bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. Wound Healing is a separate technology based on Beta-1 Glucan to aid in the management of wounds. The Company�s clinical development program run through Novogen�s subsidiaries Marshall Edwards, Inc. (MEI) and Glycotex, Inc. (Glycotex). In October 2013, Novogen Limited acquired a drug technology.